It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The human hematopoietic stem cell harbors remarkable regenerative potential that can be harnessed therapeutically. During early development, hematopoietic stem cells in the fetal liver undergo active expansion while simultaneously retaining robust engraftment capacity, yet the underlying molecular program responsible for their efficient engraftment remains unclear. Here, we profile 26,407 fetal liver cells at both the transcriptional and protein level including ~7,000 highly enriched and functional fetal liver hematopoietic stem cells to establish a detailed molecular signature of engraftment potential. Integration of transcript and linked cell surface marker expression reveals a generalizable signature defining functional fetal liver hematopoietic stem cells and allows for the stratification of enrichment strategies with high translational potential. More precisely, our integrated analysis identifies CD201 (endothelial protein C receptor (EPCR), encoded by PROCR) as a marker that can specifically enrich for engraftment potential. This comprehensive, multi-modal profiling of engraftment capacity connects a critical biological function at a key developmental timepoint with its underlying molecular drivers. As such, it serves as a useful resource for the field and forms the basis for further biological exploration of strategies to retain the engraftment potential of hematopoietic stem cells ex vivo or induce this potential during in vitro hematopoietic stem cell generation.
During human embryonic development, haematopoietic stem cells of the foetal liver undergo expansion, while retaining engraftment capacity. Here the authors apply CITE-seq to profile single cells from a human foetal liver, identifying a molecular signature of engraftment potential
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Boston University, Section of Hematology and Medical Oncology, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); Boston University and Boston Medical Center, Center for Regenerative Medicine (CReM), Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)
2 Boston University and Boston Medical Center, Center for Regenerative Medicine (CReM), Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)
3 Boston University, Division of Computational Biomedicine, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)
4 Ragon Institute of MGH, MIT and Harvard, Cambridge, USA (GRID:grid.461656.6) (ISNI:0000 0004 0489 3491)
5 Boston University, Section of Hematology and Medical Oncology, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); Boston University, Division of Computational Biomedicine, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)
6 Boston University, Department of Pathology and Laboratory Medicine, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558); Boston University, Flow Cytometry Core Facility, School of Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558)